Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ahmed Elkamhawy, Sora Paik, Hyeon Jeong Kim, Jong-Hyun Park, Ashwini M. Londhe, Kyeong Lee, Ae Nim Pae, Ki Duk Park & Eun Joo Roh. (2020) Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 1568-1580.
Read now
Read now
Wonsuk Shin, Kyoung Soo Lim, Min-Kyoung Kim, Hyun Sook Kim, Jihwa Hong, Stanford Jhee, Joseph Kim, Sungeun Yoo, Yeon-Tae Chung, Jae Moon Lee & Doo-Yeoun Cho. (2019) A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers. Drug Design, Development and Therapy 13, pages 1011-1022.
Read now
Read now
Bin Liu, Chaonan Lv, Jinxia Zhang, Ying Liu, Jing Sun, Xiaohua Cheng, Wenjing Mao, Yuanyuan Ma & Shiying Li. (2017) Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson’s disease. Neurological Research 39:5, pages 459-467.
Read now
Read now
Articles from other publishers (17)
Ashraf K. El-Damasy, Jong Eun Park, Hyun Ji Kim, Jinhyuk Lee, Eun-Kyoung Bang, Hoon Kim & Gyochang Keum. (2023) Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors. Pharmaceuticals 16:1, pages 83.
Crossref
Crossref
Ahmed Elkamhawy, Hyeon Jeong Kim, Mohamed H. Elsherbeny, Sora Paik, Jong-Hyun Park, Lizaveta Gotina, Magda H. Abdellattif, Noha A. Gouda, Jungsook Cho, Kyeong Lee, Ae Nim Pae, Ki Duk Park & Eun Joo Roh. (2021) Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action. Bioorganic Chemistry 116, pages 105352.
Crossref
Crossref
Min-Ho Nam, Jong-Hyun Park, Hyo Jung Song, Ji Won Choi, Siwon Kim, Bo Ko Jang, Hyung Ho Yoon, Jun Young Heo, Hyowon Lee, Heeyoung An, Hyeon Jeong Kim, Sun Jun Park, Doo-Wan Cho, Young-Su Yang, Su-Cheol Han, Sangwook Kim, Soo-Jin Oh, Sang Ryong Jeon, Ki Duk Park & C. Justin Lee. (2021) KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease. Neurotherapeutics 18:3, pages 1729-1747.
Crossref
Crossref
Sri Jayanti, Rita Moretti, Claudio Tiribelli & Silvia Gazzin. (2021) Bilirubin: A Promising Therapy for Parkinson’s Disease. International Journal of Molecular Sciences 22:12, pages 6223.
Crossref
Crossref
Marco Gallazzi, Marco Mauri, Maria Laura Bianchi, Giulio Riboldazzi, Lucia Princiotta Cariddi, Federico Carimati, Valentina Rebecchi & Maurizio Versino. (2021) Selegiline reduces daytime sleepiness in patients with Parkinson's disease. Brain and Behavior 11:5.
Crossref
Crossref
Ariana Q. Farrand, Ryan S. Verner, Ryan M. McGuire, Kristi L. Helke, Vanessa K. Hinson & Heather A. Boger. (2020) Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease. Brain Stimulation 13:5, pages 1323-1332.
Crossref
Crossref
Min-Ho Nam, Moosung Park, Hyeri Park, Youngjae Kim, Seulki Yoon, Vikram Shahaji Sawant, Ji Won Choi, Jong-Hyun Park, Ki Duk Park, Sun-Joon Min, C. Justin Lee & Hyunah Choo. (2017) Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease. ACS Chemical Neuroscience 8:7, pages 1519-1529.
Crossref
Crossref
Zhaofei Yang, Xuan Wang, Jian Yang, Min Sun, Yong Wang & Xiaomin Wang. (2016) Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic l-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells. Neurotoxicity Research 31:3, pages 334-347.
Crossref
Crossref
Dan-dan Yang, Riu Wang, Jin-long Zhu, Qi-yue Cao, Jie Qin, Hai-liang Zhu & Shao-song Qian. (2017) Synthesis, crystal structures, molecular docking, in vitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid. Journal of Molecular Structure 1128, pages 493-498.
Crossref
Crossref
Alexey Moskalev, Elizaveta Chernyagina, Vasily Tsvetkov, Alexander Fedintsev, Mikhail Shaposhnikov, Vyacheslav Krut'ko, Alex Zhavoronkov & Brian K. Kennedy. (2016) Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging Cell 15:3, pages 407-415.
Crossref
Crossref
Bin Liu, Jing Sun, Jinxia Zhang, Wenjing Mao, Yuanyuan Ma, Shiying Li, Xiaohua Cheng & Chaonan Lv. (2015) Autophagy-related protein expression in the substantia nigra and eldepryl intervention in rat models of Parkinson׳s disease. Brain Research 1625, pages 180-188.
Crossref
Crossref
Daphne Robakis & Stanley Fahn. (2015) Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease. CNS Drugs 29:6, pages 433-441.
Crossref
Crossref
Yong-Xin Sun, Xiao-Hong Wang, Ai-Hua Xu & Jiu-Han Zhao. (2014) Functional polymorphisms of the MAO gene with Parkinson disease susceptibility: A meta-analysis. Journal of the Neurological Sciences 345:1-2, pages 97-105.
Crossref
Crossref
Ildikó Miklya. (2014) Essential difference between the pharmacological spectrum of (−)-deprenyl and rasagiline. Pharmacological Reports 66:3, pages 453-458.
Crossref
Crossref
Anupom Borah, Rajib Paul, Sabanum Choudhury, Amarendranath Choudhury, Bornalee Bhuyan, Anupam Das Talukdar, Manabendra Dutta Choudhury & Kochupurackal P Mohanakumar. (2013) Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action. CNS Neuroscience & Therapeutics 19:11, pages 847-853.
Crossref
Crossref
Lina Zhang, Zhiqin Zhang, Yangmei Chen, Xinyue Qin, Huadong Zhou, Chaodong Zhang, Hongbin Sun, Ronghua Tang, Jinou Zheng, Lin Yi, Liying Deng & Jinfang Li. (2013) Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. International Journal of Neuropsychopharmacology 16:7, pages 1529-1537.
Crossref
Crossref
Bradley J. Robottom, Lisa M. Shulman & William J. Weiner. (2012) Drug-Induced Movement Disorders: Emergencies and Management. Neurologic Clinics 30:1, pages 309-320.
Crossref
Crossref